A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
Latest Information Update: 30 May 2025
At a glance
- Drugs SP-0202 (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine
- Indications Pneumococcal infections
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
Most Recent Events
- 25 May 2025 Status changed from not yet recruiting to recruiting.
- 23 May 2025 New trial record